NewAmsterdam Pharma (NAMS) Expected to Announce Earnings on Wednesday

Key Points

• NewAmsterdam Pharma is expected to report its Q2 2025 earnings on August 6th, anticipating a loss of ($0.52) per share and revenue of $1.44 million.
• Analysts have given NewAmsterdam Pharma a consensus rating of "Moderate Buy" with a price target of $41.30, indicating a positive outlook from the market.
• Insider trading activity includes COO Douglas F. Kling selling over 51,000 shares while a director added to their holdings, reflecting contrasting views on the company's future.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.52) per share and revenue of $1.44 million for the quarter.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The company had revenue of $2.98 million for the quarter, compared to analysts' expectations of $1.46 million. On average, analysts expect NewAmsterdam Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NewAmsterdam Pharma Stock Down 2.4%

Shares of NewAmsterdam Pharma stock traded down $0.53 on Friday, hitting $21.28. The company's stock had a trading volume of 537,520 shares, compared to its average volume of 879,418. NewAmsterdam Pharma has a 52-week low of $14.06 and a 52-week high of $27.29. The firm has a fifty day moving average price of $20.10 and a 200-day moving average price of $20.06. The company has a market capitalization of $2.39 billion, a P/E ratio of -11.32 and a beta of -0.03.

Analyst Ratings Changes

Several equities research analysts recently commented on NAMS shares. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Citigroup started coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price objective on the stock. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. The Goldman Sachs Group started coverage on shares of NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price on the stock. Finally, Cantor Fitzgerald started coverage on shares of NewAmsterdam Pharma in a report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $41.30.

Insider Transactions at NewAmsterdam Pharma

In other news, COO Douglas F. Kling sold 100,000 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the transaction, the chief operating officer directly owned 44,000 shares in the company, valued at $848,760. This represents a 69.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director James N. Topper acquired 8,584 shares of the business's stock in a transaction dated Monday, June 16th. The shares were bought at an average price of $19.50 per share, for a total transaction of $167,388.00. Following the completion of the acquisition, the director owned 3,022,153 shares in the company, valued at approximately $58,931,983.50. This trade represents a 0.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 12,364 shares of company stock worth $236,839 and sold 198,612 shares worth $4,025,887. 20.84% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NewAmsterdam Pharma stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor acquired 29,779 shares of the company's stock, valued at approximately $610,000. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.